Piramal Pharma and Ajinomoto Bio-Pharma Join Forces in ADC Field

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services have announced a strategic collaboration to enhance ADC development and manufacturing. Piramal, a leader in antibody-drug conjugate development, and Ajinomoto, known for its AJICAP™ technology, will provide combined expertise to accelerate ADC projects. By combining Piramal's manufacturing capabilities with Ajinomoto's site-specific conjugation technology, the partnership aims to fast-track development, simplify scale-up processes, and improve access to this advanced technology.

Piramal will refer clients in need of ADC manufacturing to Ajinomoto's AJICAP™, while Ajinomoto will recommend Piramal as a manufacturing partner. A separate Material Transfer Agreement will facilitate technology sharing between the companies. This collaboration will support early-stage developers in creating safer and more effective ADCs, thereby enhancing product offerings.